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Pancreatic adenocarcinoma (PAC) is an extremely fatal malignancy 
with dismal outcome with standard treatment till date. Investigators are 
constantly in search of optimal treatment approach and radiation therapy 
(RT) remains in the centre of debate. Human pancreatic cancer cell lines 
have shown both intrinsic and hypoxia induced radio resistance, and RT has 
produced conflicting results as well in the various clinical trials. However, 
most of the American studies continued the use of RT as a potential 
treatment modality but the European school of thought is widely criticized 
for their ‘therapeutic nihilism’ towards radiation and faulty clinical trial 
designs.
This article has reviewed the available literature on the evolving role of 
RT for the management of resectable and borderline resectable PAC and 
has highlighted the increasing trend towards the use of radiotherapy in 
both adjuvant and neo adjuvant settings. With the advent of modern RT 
techniques, the acute and late toxicities are much less than the earlier time, 
and therefore augmented RT is expected to produce better clinical outcomes 







Pancreatic adenocarcinoma (PAC) is a formidable gas-
trointestinal malignancy with nearly 0.49 million of new 
cases globally in 2020 with staggering number of deaths 
of 0.46 million patients [1]. It is the 7th most common cause 
of cancer related death and the incidence and mortality 
both are much higher in countries with high human de-
velopment indexes [2]. Smoking, consumption of alcohol, 
obesity, hypercholesterolemia, diabetes are attributed as 
modifiable risk factors for PAC [3,4].
In a systematic analysis for the global burden of dis-
ease, Pourshams A et al. analysed dataset of 195 countries 
from 1990 to 2017 and found the incidence and mortality 
rates of PAC increased in almost all countries over the 
time and it is alarmingly associated with a substantial 
number of years of life lost [5]. Although there is a wide 
geographical variation, this study reported the disabil-
ity-adjusted life years as nearly 9.1 million globally in 
2017. Moreover, using The Surveillance, Epidemiology 
and End Results stat¯ database, PAC is projected to be-
come second cancer related death by 2030 in the United 
States [6].
This devastating rate of mortality and cancer burden 
has kept the investigators desperately motivated in search 
of the most effective treatment sequence for PAC and 
to explore multiagent chemotherapy (CT) regimen and 
chemoradiotherapy (CRT) as both neoadjuvant and ad-
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juvant settings [7,8]. In spite of that, no paradigm shifting 
treatment option is being established with affirmation in 
the span of nearly last 50 years and clinical outcome for 
PAC remain dismal. While radical surgery and chemother-
apy are the main treatment options with curative intent, 
radiation therapy (RT) still remains in the centre of debate 
in the treatment flowchart. Conflicting data from the pub-
lished clinical trials which mostly included radiotherapy 
with earlier techniques and obsolete dose prescriptions is 
the key reason behind the  less acceptance of RT as a po-
tential treatment modality.
This article has reviewed the available literature on the 
evolving role of RT in the management of resectable and 
borderline resectable PAC and has highlighted the con-
flicting data of the clinical trials; however there is a trend 
towards the increased use of radiotherapy in both adjuvant 
and neoadjuvant settings for the patients with PAC with 
excellent clinical outcome.
2. Relative Radioresistance of Pancreatic 
Cancer Cells
Human pancreatic cancer cells are historically consid-
ered as less responsive to external beam radiotherapy, pos-
sibly for intrinsic and hypoxia-induced radioresistance. In 
1976, Courtenay et al. reported hypoxic fraction as 25% 
for xenografted pancreatic cancer cells, which indicates 
the presence of fairly large volume of hypoxic cells [9,10]. 
In later year, Verovski et al. investigated a panel of eight 
human pancreatic cell lines and mean inactivation dose 
was reported as high as for intrinsically radioresistant tu-
mors like melanoma and glioblastoma [11]. In this context, 
the role of several hypoxic cell sensitizers, such as dorani-
dazole, curcumin, capecitabine are being investigated both 
clinically and in vitro for pancreatic carcinoma [12,13].
3. Surgery is the Mainstay of Treatment
Pancreaticoduodenectomy (Whipple procedure) fol-
lowed by adjuvant chemotherapy is considered as the 
standard of care for resectable PAC, but majority of the 
disease are either unresectable or borderline resectable 
at diagnosis. A large number of patients with apparently 
local disease on imaging already might have occult met-
astatic disease as well. Moreover, there are high propor-
tions of local recurrences and margin positive surgical 
resections (R1/R2) after Whipple procedure. As a result 
of these worse prognostic factors, 10-year overall survival 
(OS) remain less than 4% for this fatal disease, even after 
potentially curative resection [14].
4. Evolution of Clinical Trials Involving CRT
Way back in 1958, the regression of tumor was first re-
ported to get enhanced with addition of 5-fluorouracil (5-
FU) to RT in an animal model [15]. Upon this principle of 
synergistic effect of 5-FU, particularly for gastrointestinal 
tumors, a pilot study was undertaken for the patients with 
locally advanced or unresectable adenocarcinoma stom-
ach, pancreas and large bowel [16]. Each patient was treat-
ed with 900-1200 rads per week to a total tumour dose of 
3500-4000 rads, 6 fractions each week along with either 
5-FU or placebo. RT portal was planned to encompass 
the entire clinical target volume but not larger than 20 cm 
x 20 cm. Survival benefit was noted for all subsets with 
strikingly better outcome for gastric and pancreatic carci-
noma.
4.1 Gastrointestinal Tumor Study Group (GITSG)
The first multicentre, randomized control trial to assess 
the effect of adjuvant CRT was initiated by GITSG in the 
United States between 1974 to 1982 [17]. This study was 
stopped early due to poor accrual, however, it showed a 
longer median survival (21.0 months vs. 10.9 months; p 
< 0.05) and better 2-year survival (43% vs. 19%) in the 
group treated with adjuvant CRT. An additional thirty 
patients were later enrolled to adjuvant CRT arm and the 
result still confirmed the survival benefit seen in the origi-
nal study. Based on such encouraging findings, use of ad-
juvant CRT for PAC was started particularly in the United 
States.
4.2 Inferior Result with CRT in European 
Organisation for Research and Treatment of 
Cancer (EORTC) & European Study Group for 
Pancreatic Cancer-1 (ESPAC-1) trial
To validate the prior results of GITSG, EORTC started 
randomization of 218 patients with pancreatic head car-
cinoma and periampullary carcinoma (between 1987 and 
1995) into two groups: adjuvant CRT versus observation 
alone after surgery [18]. RT was delivered as 40 Gy in a 
split-dose schedule with concurrent continuous infusional 
5-FU. No further maintenance chemotherapy was admin-
istered. Median survival and OS in adjuvant CRT arm 
failed to achieve any statistically significant difference. 
Subsequently ESPAC-1 Trial was initiated in 11 Euro-
pean countries in 1994 and randomized 289 patients with 
resected pancreatic ductal carcinoma into 4 arms by 2x2 
factorial design: CRT (n=73) or CT ( n=75) neither treat-
ment (n=69), or both treatments (n=72) [19]. Nearly half of 
the patient population had regional node positive disease, 
whereas positive margin and local invasion found during 
surgery were reported as 18% and 20 % respectively. RT 
was delivered in 40 Gy/split dose schedule along with 
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intravenous bolus of 5-FU in first three days of radiother-
apy. CT consisted of an intravenous bolus of leucovorin, 
followed by an intravenous bolus of 5-FU for 5 consec-
utive days for six cycles. This study found adjuvant CT 
to produce a significant survival benefit in patients with 
resected PAC, whereas CRT had a deleterious effect on 
survival. The estimated five-year survival rate was 10 % 
in CRT arm, however it was 20 % among patients who did 
not receive CRT (P=0.05). Taken at face value, results of 
EORTC and ESPAC-1 study uphold the notion that adju-
vant CRT should not be administered routinely for poten-
tially resected PAC.
Counteract the inferior results
Inferior results with the administration of adjuvant 
CRT as demonstrated by EORTC and ESPAC-1 should be 
interpreted with caution and subsequent ‘therapeutic nihil-
ism’ about radiotherapy should be addressed keeping the 
following factors in mind [20]:
a) These trials including GITSG, EORTC and ES-
PAC-1 used a low total dose of RT in an obsolete dose 
schedule. Split dose fractions are radiobiologically inferi-
or because of the accelerated repopulation of tumor clono-
gens and is no longer used in current practice.
b) Non conformal techniques (AP-PA fashion) for 
abdominal RT would invariably result into high treat-
ment-related toxicity and decreased survival of the pa-
tients.
c) No details of quality assurance (QA) for RT are 
available. Surgery, or pathological findings are not docu-
mented thoroughly. 
d) Trials are underpowered and some of them included 
heterogeneous tumor sites. Clinical outcomes of periam-
pulary carcinoma would be better than PAC and this might 
influence the overall analysis.
e) More than 20% of patients in CRT arm did not 
receive the intended treatment because of postoperative 
complications or lack of compliance in EORTC trial. Not 
receiving maintenance chemotherapy, unlike GITSG study 
might be another reason of inferior result with CRT in this 
particular trial.
Inferior outcome of ESPAC-1 trial has led to subse-
quent omission of adjuvant RT from most of the adjuvant 
trials in Europe, including ESPAC-3 and ESPAC-4 [21,22]. 
The publication of CONKO-001 (Charité Onkologie 001) 
trial, which was conducted from 1998 to 2004 in Germany 
and Austria further reduced the practice of adjuvant RT for 
the patients with locally advanced PAC and adjuvant gemcit-
abine without RT became the standard of treatment [23].
4.3 Continuing Use of CRT in the United States
American studies involving the management of PAC 
remained inquisitive regarding the role of radiation and 
GITSG trial laid the foundation for continuing use of CRT 
in the United States. 
At Mayo clinic in Rochester, 472 patients with PAC 
were evaluated retrospectively who underwent R0 resec-
tion between 1975 and 2005 and 274 patients received 
adjuvant RT [24]. 45 Gy in 25 fractions was delivered to the 
tumor bed and regional nodes with a four-field technique 
followed by an additional 5.4 to 9 Gy boost to the tumor 
bed. This study reported survival benefit with adjuvant 
CRT (Median survival 25.2 versus 19.2 months, p=.001). 
Positive LN and high histologic grade were identified as 
adverse prognostic factors. 
Despite the heterogeneous results of the randomized 
phase III trials, several nonrandomized, single institute 
US series have consistently demonstrated survival benefit 
with the addition of adjuvant CRT for resected pancreatic 
cancer. Studies conducted at Johns Hopkins University, 
and an analyses of the National Cancer Institute's Surveil-
lance, Epidemiology, and End Results (SEER) database 
are the examples to be mentioned with special emphasis 
[25,26].
In this context, Radiation Therapy Oncology Group 
(RTOG)/Gastrointestinal Intergroup trial 9704 was de-
signed to compare 5-FU versus gemcitabine based CT, 3 
weeks prior to CRT and 12 weeks after CRT [17,27]. CRT in 
both arms consisted of 50.4 Gy delivered in 28 fractions 
(5 days per week) with continuous 5-FU infusion (250 
mg/m2/d). RT was delivered to the tumor bed and region-
al nodes, defined by preoperative CT imaging. Regional 
nodal stations particularly pancreatic, celiac, mesenteric, 
periaortic, duodenal, and hepatic portal lymph nodes were 
included in the RT fields. After an initial dose of 45 Gy, a 
boost dose of 5.4 Gy was delivered to the tumor bed only. 
This study included CRT in the both treatment arms and 
therefore, the independent effect of CRT cannot be as-
sessed. However, it is the largest randomised clinical trial 
(RCT) that used CRT in the adjuvant settings affirming 
its contributing role in the management of PAC. Survival 
benefit at 3 years was demonstrated with the use gemcit-
abine, but it got disappeared on 5 years of follow up and a 
large percentage of distant relapse (73%) were reported [28]. 
Hence, any improvement in survival associated with the 
use of gemcitabine appears to be temporary and marginal.
These findings prompted the investigators to design a 
further phase III adjuvant trial to evaluate the impact of 
CRT after completion of a full course of gemcitabine (NRG 
Oncology/RTOG 0848) [29]. In the first randomization the 
impact of the addition of erlotinib to gemcitabine is being 
tested. After 5 cycles of gemcitabine based therapy, if 
no evidence of disease progression is found on imaging, 
DOI: https://doi.org/10.30564/jor.v3i2.3646
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a second randomization evaluating the impact of CRT 
would take place. Notable point for this trial is inclusion 
of 16% of patient population with histologically positive 
margins. Result of step 1 indicates addition of erlotinib to 
gemcitabine did not provide survival benefit and the an-
swer regarding the role of adjuvant RT is still awaited.
4.4 Role of Neo Adjuvant RT
Neoadjuvant therapy is believed to produce potential 
advantages over upfront surgery in patients with localized 
PAC. With the increased possibility of R0 resection, this 
approach may lead to a better survival rate and is becom-
ing more acceptable alternative over the years. Further-
more, a vast majority of the patients fail to recover suffi-
ciently or in time after the morbid and extensive surgery 
leading to the omission or delay of the adjuvant treatment 
[30]. A meta analysis of 38 studies with the resectable or 
borderline resectable pancreatic cancer patients reported 
improved OS by intention to treat with neoadjuvant thera-
py, despite a drop in the resection rate [31].
The Dutch PREOPANC-1 trial compared neoadjuvant 
gemcitabine-based CRT to upfront surgery, followed by 
adjuvant gemcitabine in the both arms [32]. Although OS 
benefit was not demonstrated, all secondary outcomes 
found superiority in neoadjuvant arm. Rate of R0 resec-
tion, disease free survival, and locoregional recurrence 
free interval were significantly better with neoadjuvant 
CRT [33].
With the wide introduction of FOLFIRINOX (5-FU, 
leucovorin, irinotecan, and oxaliplatin) in the subsequent 
years as a superior multiagent chemotherapy, PREO-
PANC-2 trial is further designed with the aim of direct 
comparison between total neoadjuvant FOLFIRINOX and 
gemcitabine based CRT [34]. The trial is actively recruiting 
at present and the result will definitely guide us in future 
to choose the best neoadjuvant protocol for resectable and 
borderline resectable PAC.
4.5 Role of Stereotactic Body Radiation Therapy 
(SBRT)
Role of SBRT is emerging for the management of PAC, 
since the outcome of conventional CRT is considered 
suboptimal. With the administration of high dose RT with 
extreme conformity, the effect of radiation is certainly be-
ing augmented and a plethora of clinical trials has demon-
strated excellent local control with minimal acute and late 
toxicity [35-37]. However; the detail discussion of technical 
feasibility and outcome of SBRT is beyond the scope of 
this review.
5. Conclusions
Combined modality of treatment is now the accepted 
rule for the management of PAC, and the role of radio-
therapy is being constantly evaluated to get optimally fit 
into the treatment algorithm. While the margin positive 
resection and pathologically positive lymph nodes are 
widely accepted indications for adjuvant CRT, routine 
use of adjuvant RT is debatable. A total dose of 45-54 Gy 
to the tumor bed in conventional fractionation schedule 
is usually accepted, but the elective nodal irradiation and 
the inclusion of anastomotic sites are not universally fol-
lowed.
RT has demonstrated adequate efficacy to control pain 
and obstructive symptoms by shrinking local disease and 
facilitates R0 resection if administered in neoadjuvant 
settings. SBRT to a total dose of 30-45 Gy in 3 to 5 frac-
tions can produce excellent local control and presently its 
role is under evaluation by a plethora of clinical trials. At 
the time of writing this article, a database of more than 
hundred clinical trials of SBRT in pancreatic cancer is 
showing with the search in https://clinicaltrials.gov/ [38]. 
However, extreme caution need to be taken to minimise 
the dose to the OARs and respiratory motion management 
is the another challenge to be dealt with modern radiother-
apy techniques.
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